Revenue grew 29% at CER in Q2 2026, with strong gains in Haematology and Immunology segments and a 53% increase in strategic portfolio revenue. Positive pivotal data for pozdeutinurad in gout and the Arthrosi acquisition strengthen the pipeline. Net debt rose due to the acquisition.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.